Biohaven data at 2022 american academy of neurology (aan) annual meeting demonstrate leadership in migraine and commitment to advancing potential new therapeutic options in neurological diseases

Migraine patients treated with nurtec odt had a reduction in total opioid prescriptions filled after initiation of therapy, according to an analysis of real-world administrative claims single and multiple daily doses of intranasal zavegepant of up to 40 mg were well tolerated in phase 1 study rimegepant, atogepant and monoclonal antibody treatments determined to be effective options for the prevention of migraine when compared vs placebo new haven, conn. , march 31, 2022 /prnewswire/ -- biohaven pharmaceutical holding company ltd.
BHVN Ratings Summary
BHVN Quant Ranking